Elise-Marie Minoc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elise-Marie Minoc has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Basile Chrétien
Pharmacology Department, CHU de Caen, 14000 Caen, France
2 shared publicationsCharles Dolladille
Pharmacology Department, CHU de Caen, 14000 Caen, France; Psychiatric Department, CHU de Caen, 14000 Caen, France
2 shared publicationsCédric Villain
Geriatric Department, CHU de Caen, 14000 Caen, France; UNICAEN, Inserm COMETE, U1075, Normandie University, 14000 Caen, France
2 shared publicationsMarie Heraudeau
UNICAEN, Inserm COMETE, U1075, Normandie University, 14000 Caen, France; Pharmacology Department, CHU de Caen, 14000 Caen, France
2 shared publicationsSoumia Benbrika
Psychiatric Department, CHU de Caen, 14000 Caen, France; UNICAEN, Inserm, UMR 1237, Normandie University, 14000 Caen, France
2 shared publicationsVéronique Lelong-Boulouard
UNICAEN, Inserm COMETE, U1075, Normandie University, 14000 Caen, France; Pharmacology Department, CHU de Caen, 14000 Caen, France
2 shared publications
Latest Publications
- Open Access
Association between exposure to proton pump inhibitors and delirium: a descriptive and disproportionality analysis of VigiBase
Objectives Proton pump inhibitor (PPI) exposure can lead to hyponatraemia, which is a common cause of delirium. An association between PPI exposure and delirium without hyponatraemia has been suggested in the literature. We aimed to describe the association between reports of delirium and PPI exposure and to assess the association between PPI and delirium with and without hyponatraemia. Design A descriptive and disproportionality analysis of claims data. Setting World pharmacovigilance database VigiBase between 1 January 1991 and 9 February 2022. Primary and secondary outcome measures In the first part, we described reports of delirium for which involvement of a PPI or interactions of PPIs with other drugs were suspected. In the second part, delirium cases and non-cases were used to assess the disproportionality signal using the reporting OR (ROR) for the associations of PPI exposure with delirium or delirium/hyponatraemia co-events. Results We identified 2395 reports of delirium in which involvement of PPI exposure was suspected. Omeprazole, esomeprazole and pantoprazole were the most frequently reported PPIs. Hyponatraemia was present in 11% of the reports. The disproportionality analysis included 1 264 798 reports of adverse drug reactions in patients using PPIs, including 19 081 reports of delirium. We did not find a disproportionality signal for the association between PPI use and delirium (ROR 0.89, 95% CI 0.87 to 0.91). We detected an association of PPI use with delirium/hyponatraemia co-events (ROR 1.53, 95% CI 1.41 to 1.65). Conclusions Most reports of delirium in which the involvement of PPIs was suspected did not include concomitant hyponatraemia. However, no significant signal of disproportionate reporting of delirium was observed for PPIs compared with other drugs, except in cases of delirium associated with hyponatraemia. Hyponatraemia may be the main mechanism linking PPI exposure with delirium, and this possibility should be further explored in prospective studies. Trial registration number NCT05815550.
Open AccessAssociation between exposure to proton pump inhibitors and delirium: a descriptive and disproportionality analysis of VigiBase
Objectives Proton pump inhibitor (PPI) exposure can lead to hyponatraemia, which is a common cause of delirium. An association between PPI exposure and delirium without hyponatraemia has been suggested in the literature. We aimed to describe the association between reports of delirium and PPI exposure and to assess the association between PPI and delirium with and without hyponatraemia. Design A descriptive and disproportionality analysis of claims data. Setting World pharmacovigilance database VigiBase between 1 January 1991 and 9 February 2022. Primary and secondary outcome measures In the first part, we described reports of delirium for which involvement of a PPI or interactions of PPIs with other drugs were suspected. In the second part, delirium cases and non-cases were used to assess the disproportionality signal using the reporting OR (ROR) for the associations of PPI exposure with delirium or delirium/hyponatraemia co-events. Results We identified 2395 reports of delirium in which involvement of PPI exposure was suspected. Omeprazole, esomeprazole and pantoprazole were the most frequently reported PPIs. Hyponatraemia was present in 11% of the reports. The disproportionality analysis included 1 264 798 reports of adverse drug reactions in patients using PPIs, including 19 081 reports of delirium. We did not find a disproportionality signal for the association between PPI use and delirium (ROR 0.89, 95% CI 0.87 to 0.91). We detected an association of PPI use with delirium/hyponatraemia co-events (ROR 1.53, 95% CI 1.41 to 1.65). Conclusions Most reports of delirium in which the involvement of PPIs was suspected did not include concomitant hyponatraemia. However, no significant signal of disproportionate reporting of delirium was observed for PPIs compared with other drugs, except in cases of delirium associated with hyponatraemia. Hyponatraemia may be the main mechanism linking PPI exposure with delirium, and this possibility should be further explored in prospective studies. Trial registration number NCT05815550.
- Open Access
- 31 January 2024
- Published by Springer Nature in Research Square
Association between antidepressant use and delirium in older adults: an analysis of the World Health Organization’s global pharmacovigilance database
Background Psychoactive drugs frequently cause delirium adverse events in older adults. However, few data on the relationship between antidepressants and delirium are available. Here, we investigated the association between antidepressant prescription and pharmacovigilance reports of delirium in older adults. Methods Using the World Health Organization’s VigiBase® global pharmacovigilance database from 1967 to 2022, we performed a disproportionality analysis in order to probe the putative associations between each antidepressant class (non-selective monoamine reuptake inhibitors (NSMRIs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), alpha-2-adrenergic receptor antagonists, and other antidepressants) and reports of delirium in people aged 65 or over. We calculated the reporting odds ratios (r-OR) and their 95% confidence interval ([95%CI]) with logistic regression models before and after adjustment for confounding factors. Secondary analyses were performed for each drug and within each class by age group (65–74, and 75 and over). We also studied the reports of concomitant delirium and hyponatremia. Results Our main analysis included 87,524 cases of delirium. After adjustment for confounders, a significant association was found between delirium and all antidepressant classes other than SNRIs. Intraclass disparities were found for the association between the most frequently prescribed antidepressants and reports of delirium. An elevated risk of reports of concomitant delirium and hyponatremia was found for SSRIs (4.46 [4.01–4.96]), SNRIs (1.25 [1.07–1.46]), MAOIs (1.72 [1.41–2.09]), and the “other antidepressants” class (1.47 [1.30–1.65]). Conclusions There was a significant association between reports of delirium and antidepressant classes (other than SNRIs). However, this association varied from one drug to another within a given antidepressant class. Moreover, this association could not always be explained by antidepressant-induced hyponatremia.
- 31 January 2024
- Published by Springer Nature in Research Square
Open AccessAssociation between antidepressant use and delirium in older adults: an analysis of the World Health Organization’s global pharmacovigilance database
Background Psychoactive drugs frequently cause delirium adverse events in older adults. However, few data on the relationship between antidepressants and delirium are available. Here, we investigated the association between antidepressant prescription and pharmacovigilance reports of delirium in older adults. Methods Using the World Health Organization’s VigiBase® global pharmacovigilance database from 1967 to 2022, we performed a disproportionality analysis in order to probe the putative associations between each antidepressant class (non-selective monoamine reuptake inhibitors (NSMRIs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), alpha-2-adrenergic receptor antagonists, and other antidepressants) and reports of delirium in people aged 65 or over. We calculated the reporting odds ratios (r-OR) and their 95% confidence interval ([95%CI]) with logistic regression models before and after adjustment for confounding factors. Secondary analyses were performed for each drug and within each class by age group (65–74, and 75 and over). We also studied the reports of concomitant delirium and hyponatremia. Results Our main analysis included 87,524 cases of delirium. After adjustment for confounders, a significant association was found between delirium and all antidepressant classes other than SNRIs. Intraclass disparities were found for the association between the most frequently prescribed antidepressants and reports of delirium. An elevated risk of reports of concomitant delirium and hyponatremia was found for SSRIs (4.46 [4.01–4.96]), SNRIs (1.25 [1.07–1.46]), MAOIs (1.72 [1.41–2.09]), and the “other antidepressants” class (1.47 [1.30–1.65]). Conclusions There was a significant association between reports of delirium and antidepressant classes (other than SNRIs). However, this association varied from one drug to another within a given antidepressant class. Moreover, this association could not always be explained by antidepressant-induced hyponatremia.